Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06408181 · ClinicalTrials.gov registry record · Phase 3
APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia
A Phase 3 study of Preeclampsia and Pregnancy Loss, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,150
- Enrollment target
- 1
- Study location
NCT06408181: Recruiting Phase 3 study of Preeclampsia and Pregnancy Loss, sponsored by University of Pennsylvania.
NCT06408181 is a Phase 3 study of Preeclampsia and Pregnancy Loss that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 1,150 participants, roughly in line with the 1,102-participant average among 48 other Preeclampsia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06408181, a Phase 3 study of Preeclampsia and Pregnancy Loss, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,150 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.
Primary Outcome
defined as two blood pressures (BPs) ≥ 140/90 mmHg at least 4 hours apart with proteinuria
Conditions Studied
Interventions
- DRUG Aspirin 162 mg
- DRUG Aspirin 81mg
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,150 participants |
| Start Date | 2024-06-12 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
What NCT06408181 shows while recruiting
NCT06408181 is an interventional study that assigns participants to a tested intervention. Its 1,150 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,102-participant average among 48 other Preeclampsia trials with a reported enrollment target.
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Aspirin 162 mg is the first listed.
NCT06408181 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06408181 about?
NCT06408181 is a clinical study titled "APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia". The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and ti...
What is the current status of trial NCT06408181?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,150 participants. The study started on 2024-06-12. Estimated completion is 2029-06.
What conditions does trial NCT06408181 study?
This clinical trial studies the following conditions: Preeclampsia, Pregnancy Loss.
What interventions are being tested in trial NCT06408181?
The interventions under investigation include: Aspirin 162 mg (DRUG), Aspirin 81mg (DRUG).
Who is sponsoring clinical trial NCT06408181?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06408181 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06408181's enrollment target sits among peer trials
1,150 5th of 48 higher than 44 of 48 other Preeclampsia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preeclampsia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preeclampsia Postpartum Antihypertensive Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
ACTIVE NOT RECRUITING · Phase 3
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06528314 · 1,150 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- NCT07293559 · 1,150 participants
Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- NCT07339423 · 1,150 participants · Phase 3
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
- NCT05564026 · 1,151 participants
Molecular Epidemiology of Pediatric Germ Cell Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI